6XP Stock Chart & Stats
€0.91
€0.03(2.31%)
At close: 4:00 PM EDT
€0.91
€0.03(2.31%)
Day’s Range― - ―
52-Week Range€0.78 - €3.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€45.11M
Enterprise Value€645.43M
Total Cash (Recent Filing)€179.91M
Total Debt (Recent Filing)€147.30M
Price to Earnings (P/E)―
Beta1.17
Next Earnings
Nov 04, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.86
Shares Outstanding47,416,573
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.00
Price to Sales (P/S)0.00
P/FCF Ratio-5.44
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.57
Revenue Forecast (FY)€8.67M
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthSubstantial equity relative to debt provides a stronger financial base than the company’s operating results alone would suggest. Moderate leverage may preserve some flexibility to fund development and pursue partnerships, although continued losses could gradually reduce this cushion.
Improving Loss TrendThe reduction in net losses from the 2024 trough indicates some improvement in financial performance, even though profitability remains distant. If maintained, better loss control could extend financial runway and reduce the pace at which equity resources are consumed.
HyNap Formulation PlatformA technology platform focused on reformulating established medicines gives Xspray multiple potential development opportunities rather than reliance on a single novel drug. Targeting bioequivalent or differentiated products also supports partnership and licensing pathways.
Bears Say
No Commercial RevenueThe absence of reported revenue shows that Xspray has not yet established commercial monetization from its development portfolio. Until approvals, licensing payments, or product uptake begin, the business lacks an operating revenue base to offset research and development costs.
Persistent Cash BurnSustained negative operating and free cash flow means the company is consuming cash while advancing its pipeline. This limits internally funded growth and makes continued access to financing, licensing proceeds, or other capital important for maintaining development activities.
Rising Leverage And Funding DependenceAlthough leverage remains moderate, its increase from earlier years alongside ongoing cash outflows signals growing reliance on external capital. If losses persist, additional financing could become necessary and may constrain strategic flexibility or increase financial pressure.
Xspray Pharma AB News
6XP FAQ
What was Xspray Pharma AB’s price range in the past 12 months?
Xspray Pharma AB lowest stock price was €0.78 and its highest was €3.05 in the past 12 months.
What is Xspray Pharma AB’s market cap?
Xspray Pharma AB’s market cap is €45.11M.
When is Xspray Pharma AB’s upcoming earnings report date?
Xspray Pharma AB’s upcoming earnings report date is Nov 04, 2026 which is in 19 days.
How were Xspray Pharma AB’s earnings last quarter?
Xspray Pharma AB released its earnings results on Aug 05, 2026. The company reported -€0.079 earnings per share for the quarter.
Is Xspray Pharma AB overvalued?
According to Wall Street analysts Xspray Pharma AB’s price is currently Overvalued.
Does Xspray Pharma AB pay dividends?
Xspray Pharma AB does not currently pay dividends.
What is Xspray Pharma AB’s EPS estimate?
Xspray Pharma AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Xspray Pharma AB have?
Xspray Pharma AB has 47,416,573 shares outstanding.
What happened to Xspray Pharma AB’s price movement after its last earnings report?
Xspray Pharma AB reported an EPS of -€0.079 in its last earnings report. Following the earnings report the stock price went down -1.036%.
Which hedge fund is a major shareholder of Xspray Pharma AB?
Currently, no hedge funds are holding shares in DE:6XP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Xspray Pharma AB
Xspray Pharma AB (publ), a pharmaceutical firm based in Solna, Sweden, specializes in developing protein kinase inhibitors for precise cancer treatments. Their current drug pipeline includes HyNap-Nilo, aimed at chronic myeloid leukemia; HyNap-Sora, which targets renal, liver, and several types of thyroid cancer; and HyNap-Dasa, intended for both chronic myeloid leukemia and acute lymphoblastic leukemia. Established in 2003, the company was formerly known as Xspray Microparticles AB until its name change to Xspray Pharma AB (publ) in 2017.
Technical Analysis
Camurus AB
―
Vicore Pharma Holding AB
―
Xbrane Biopharma AB
―
Spago Nanomedical AB
―
Bio-Works Technologies AB
―